Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Bioventus (BVS) Divestments (2022 - 2023)

Bioventus filings provide 1 years of Divestments readings, the most recent being -$46.4 million for Q4 2023.

On a quarterly basis, Divestments changed N/A to -$46.4 million in Q4 2023 year-over-year; TTM through Sep 2024 was -$46.4 million, a 232.97% decrease, with the full-year FY2023 number at -$11.5 million, changed N/A from a year prior.
Divestments hit -$46.4 million in Q4 2023 for Bioventus, down from $46.4 million in the prior quarter.
In the past five years, Divestments ranged from a high of $46.4 million in Q3 2023 to a low of -$46.4 million in Q4 2023.